{
  "author": {
    "name": "Anushree Dave",
    "webUrl": "/author/profile/anushree-dave/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 1,
    "social": [],
    "articles": [
      {
        "uri": "/2021/11/22/health-insurers-balk-at-biogens-56000-a-year-alzheimers-treatment/",
        "title": "Health insurers balk at Biogen's $56,000-a-year Alzheimer's treatment",
        "byline": "John Tozzi, Angelica LaVito and Anushree Dave",
        "kicker": "Market Insights",
        "prettyDate": "November 22, 2021",
        "timeToRead": "7 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2021/11/Biogen-Article-202111191057.jpg",
          "width": "496",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/john-tozzi-angelica-lavito/",
            "name": "John Tozzi, Angelica LaVito"
          },
          {
            "webUrl": "/author/profile/anushree-dave/",
            "name": "Anushree Dave"
          }
        ],
        "kickerNode": [
          {
            "uri": "/market-insights/",
            "sectionName": "Market Insights"
          }
        ],
        "summary": "Private insurers say they need more evidence that the treatment actually slows the rate at which Alzheimer's patients deteriorate.",
        "body": null
      }
    ]
  }
}